These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22771546)

  • 1. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
    Rattanakiat S; Nishikawa M; Takakura Y
    Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
    Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK
    J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
    Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice.
    Zhu FG; Kandimalla ER; Yu D; Tang JX; Agrawal S
    Int Immunopharmacol; 2004 Jul; 4(7):851-62. PubMed ID: 15182725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
    Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
    Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
    Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.
    Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
    Pharm Res; 2005 Oct; 22(10):1627-33. PubMed ID: 16180119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
    Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
    Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
    Inoue J; Aramaki Y
    Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
    Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
    Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice.
    Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
    J Control Release; 2005 Nov; 108(2-3):294-305. PubMed ID: 16209897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
    Zhang XQ; Dahle CE; Weiner GJ; Salem AK
    J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
    Shima F; Uto T; Akagi T; Akashi M
    Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen.
    Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK
    Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.